The 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer.
AffiliationCRUK Department of Medical Oncology, Christie Hospital NHS Trust, Withington, Manchester, UK. Howell@christie-tr.nwest.nhs.uk
MetadataShow full item record
AbstractThe ATAC trial is the first study to compare a third-generation aromatase inhibitor (AI), anastrozole, with tamoxifen for the adjuvant treatment of early breast cancer. Analyses at 33 and 47 months of median follow-up showed that anastrozole significantly prolonged disease-free survival (DFS) and time to recurrence (TTR), and reduced the incidence of contralateral breast cancer, compared with tamoxifen. Results of the Completed Treatment Analysis at 68 months of median follow-up confirmed the superiority of anastrozole over tamoxifen. The absolute difference in DFS between anastrozole and tamoxifen continued to increase beyond completion of treatment and early improvements in DFS and TTR have translated into a benefit in time to distant recurrence. Benefits of anastrozole over tamoxifen were maintained without a detrimental impact on quality of life. Mature safety data with extensive patient exposure indicate that overall, anastrozole has a favourable safety profile compared with tamoxifen. Importantly, a decrease in the odds ratio of cardiovascular events was observed with anastrozole compared with tamoxifen. The ATAC trial provides the most mature data of any AI trial and has enabled the evaluation of a full risk:benefit profile of anastrozole.
CitationThe 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) Trial: a step forward in the treatment of early breast cancer. 2006, 1 (3):207-15 Rev Recent Clin Trials
JournalReviews on Recent Clinical Trials
- Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
- Authors: Aapro MS, Forbes JF
- Issue date: 2003
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
- Authors: Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group
- Issue date: 2003 Nov 1
- 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
- Authors: Buzdar AU, ATAC trialists' group
- Issue date: 2003 Sep
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
- Authors: Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M
- Issue date: 2008 Jan
- Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
- Authors: Hillner BE
- Issue date: 2004 Sep 15